Toroso Investments LLC Grows Position in Edwards Lifesciences Co. (NYSE:EW)

Toroso Investments LLC lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 5.5% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 13,351 shares of the medical research company’s stock after buying an additional 698 shares during the quarter. Toroso Investments LLC’s holdings in Edwards Lifesciences were worth $1,103,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Marshall Wace LLP grew its position in Edwards Lifesciences by 167.5% in the third quarter. Marshall Wace LLP now owns 3,512,312 shares of the medical research company’s stock valued at $290,225,000 after acquiring an additional 2,199,410 shares in the last quarter. FMR LLC raised its position in shares of Edwards Lifesciences by 16.3% during the 2nd quarter. FMR LLC now owns 8,861,392 shares of the medical research company’s stock valued at $842,630,000 after acquiring an additional 1,244,420 shares in the last quarter. Artisan Partners Limited Partnership acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $78,726,000. Voya Investment Management LLC raised its position in shares of Edwards Lifesciences by 305.3% during the 2nd quarter. Voya Investment Management LLC now owns 1,218,590 shares of the medical research company’s stock valued at $115,875,000 after acquiring an additional 917,906 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in Edwards Lifesciences by 19.0% in the second quarter. Massachusetts Financial Services Co. MA now owns 5,381,049 shares of the medical research company’s stock worth $511,685,000 after buying an additional 860,313 shares during the period. 80.35% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, VP Daveen Chopra sold 4,435 shares of the firm’s stock in a transaction that occurred on Wednesday, March 15th. The shares were sold at an average price of $77.47, for a total value of $343,579.45. Following the sale, the vice president now directly owns 18,911 shares in the company, valued at approximately $1,465,035.17. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, VP Donald E. Bobo, Jr. sold 6,725 shares of Edwards Lifesciences stock in a transaction on Monday, January 9th. The shares were sold at an average price of $77.50, for a total transaction of $521,187.50. Following the completion of the transaction, the vice president now owns 62,561 shares of the company’s stock, valued at $4,848,477.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Daveen Chopra sold 4,435 shares of the firm’s stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $77.47, for a total transaction of $343,579.45. Following the completion of the sale, the vice president now owns 18,911 shares of the company’s stock, valued at $1,465,035.17. The disclosure for this sale can be found here. In the last three months, insiders have sold 101,821 shares of company stock valued at $7,902,704. 1.29% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

EW has been the topic of a number of recent analyst reports. Wolfe Research cut Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Thursday, December 1st. Truist Financial raised their price objective on shares of Edwards Lifesciences from $85.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, February 1st. Royal Bank of Canada reduced their target price on shares of Edwards Lifesciences from $118.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, November 28th. Piper Sandler downgraded shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $95.00 to $80.00 in a research report on Monday, January 30th. Finally, Morgan Stanley upped their price target on shares of Edwards Lifesciences from $92.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, January 6th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $88.95.

Edwards Lifesciences Price Performance

NYSE:EW opened at $80.74 on Friday. Edwards Lifesciences Co. has a 1-year low of $67.13 and a 1-year high of $131.10. The company has a current ratio of 3.03, a quick ratio of 2.17 and a debt-to-equity ratio of 0.10. The firm has a fifty day simple moving average of $78.35 and a 200 day simple moving average of $79.39. The stock has a market capitalization of $48.94 billion, a PE ratio of 33.09, a P/E/G ratio of 4.63 and a beta of 1.01.

Edwards Lifesciences (NYSE:EW – Get Rating) last announced its quarterly earnings results on Tuesday, January 31st. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.03. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.33 billion. Edwards Lifesciences had a return on equity of 26.05% and a net margin of 28.27%. The company’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.51 EPS. On average, research analysts expect that Edwards Lifesciences Co. will post 2.52 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

(Get Rating)

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.